Dr. Reddy’s Laboratories Secures Exclusive Distribution

Executive SummaryDr. Reddy’s Laboratories Ltd. realized a 2% share price appreciation during Friday's trading session following the announcement of a strategic partnership with Japanese multinational Takeda Pharmaceutical. Under this landmark agreement, Dr. Reddy’s has secured the exclusive rights to market and distribute Qdenga—India's first approved dengue vaccine—across the country's private market for both pediatric and adult populations. Takeda will retain full commercialization rights within the public sector and maintain oversight of the vaccine’s manufacturing and importation. Strategic Product Profile and Market PositioningQdenga represents a critical addition to Dr. Reddy’s domestic vaccine portfolio, reinforcing its position as a leading vaccine player in the region. Developed as a live-attenuated tetravalent vaccine, Qdenga is designed to offer broad protection against all four dengue virus serotypes. India's Central Drugs Standard Control Organization (CDSCO) recently granted marketing authorization for the vaccine for individuals aged 4 to 60. Commercial Outlook and Public Health ImpactThe commercial rollout of Qdenga in India is anticipated in the first half of 2027, subject to final local processing. This launch targets a substantial and rapidly expanding unmet medical need. Dengue remains one of the fastest-growing vector-borne diseases globally. In 2024, the World Health Organization reported a record 14.4 million global cases with over 11,000 fatalities, of which India accounted for 232,425 cases and 233 deaths. Additionally, recent epidemiological data indicates an 11-fold increase in reported dengue cases in India over the past two decades, with all four serotypes actively circulating.